Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916977 | 0.82 | ALDH1A1 (0.41) | CA2CNR2CA1CA12CA9 | |
| SCHEMBL4925174 | 0.80 | CA2 (0.46) | CA2CNR2CA1CA12CA9 | |
| SCHEMBL4926929 | 0.74 | NPC1 (0.45) | LMNAHTR2C | |
| SCHEMBL7987856 | 0.69 | MMP9 (0.49) | CA2CA1CA9ALDH1A1GAA | |
| SCHEMBL4928565 | 0.69 | MMP2 (0.45) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8337020 | 0.68 | CA2 (0.60) | CA2CNR2ALDH1A1LMNAHTR2A | |
| SCHEMBL11889489 | 0.67 | CA2 (0.69) | CA2CNR2ALDH1A1LMNAHTR2A | |
| Valine SCHEMBL8429982 | 0.66 | CA2 (0.49) | CA2CA1ALDH1A1LMNAGAA | |
| SCHEMBL6793165 | 0.66 | CA2 (0.67) | CA2CNR2ALDH1A1LMNAHTR2A | |
| SCHEMBL6618290 | 0.65 | CA2 (0.59) | CA2CNR2ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | claimed |
| JP-2008508348-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1796681-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | Genmedica Therapeutics SL (ES) | 2007-06-20 | — | — | EP | claimed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | claimed |
| WO-2006013209-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | GENMEDICA THERAPEUTICS SL (ES) | 2006-02-09 | — | — | WO | claimed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | CA2 3279/4885CNR2 4335/4885CA1 2819/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | CA2 3365/4885CNR2 4342/4885CA1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.